Cerebra AI — Artificial Intelligence for Fast and Accurate Diagnosis of Neuropathologies

About the Company
Cerebra AI is a Kazakhstan-based technology company specializing in the development of artificial intelligence solutions for medical diagnostics. Its primary focus is neuroimaging and radiology, particularly automated analysis of brain MRI scans.

Problem
• High workload for radiologists and neurosurgeons when analyzing MRI images;
• Shortage of qualified specialists in many regions;
• High risk of human error during diagnosis;
• Delays in diagnosis, especially in cases of stroke and other acute conditions.

Solution
The company has developed an AI system for automatic brain MRI analysis that:
• Quickly detects signs of stroke, tumors, aneurysms, and other abnormalities;
• Provides a preliminary report to help physicians reduce analysis time;
• Improves diagnostic accuracy and reduces the likelihood of errors.

Results and Impact
• Reduced diagnosis time for MRI-based assessments;
• Enhanced clinical decision support for doctors;
• Improved quality of neuropathology diagnostics, including stroke detection;
• Increased access to diagnostic services in remote regions;
• Reduced workload for medical staff.

Implementation Timeline
• 2018–2019 — Start of development and creation of MVP;
• 2020–2022 — Piloting and implementation in several clinics;
• Since 2023 — Scaling across Kazakhstan and expansion to international markets (in progress).

Partnerships and Support
Government Agencies:
• Ministry of Healthcare of the Republic of Kazakhstan;
• National Center for Neurosurgery;
• Republican Center for Electronic Healthcare.
Medical Institutions:
• Regional and national clinics, diagnostic centers, neurosurgery institutes.
Investors and Accelerators:
• Astana Hub;
• MOST Ventures and others.

Future Plans
• International certification of the product;
• Expansion to Central Asia, the CIS, and other global markets;
• Development of new AI modules for diagnosing additional diseases.